Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Big Tex House of Coin -- Ignore unavailable to you. Want to Upgrade?

To: BigTex who wrote (9380)	12/10/1999 9:22:00 AM
From: Robert B.	Read Replies (1) \| Respond to of 19297

cool! SVRI .90 X .95 now

To: BigTex who wrote (9380)	12/10/1999 10:03:00 AM
From: Spark	Read Replies (1) \| Respond to of 19297

We all know what this sort of news can do to a stock..lol..we'll see.. Friday December 10, 8:31 am Eastern Time Company Press Release HIV-VAC AIDS Vaccine Promises to Halt Rising Death Toll TORONTO--(BUSINESS WIRE)--Dec. 10, 1999--HIV-VAC, Inc., (OTC/BB: HIVC - news) today announced that Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath, the developer of HIV-VAC's AIDS vaccine, said, ''that with a record 2.6 million people dying from AIDS in 1999, and another 5.6 million infected, the only answer to halting this worldwide scourge is an effective vaccine against the disease. I believe our HIV-VAC AIDS vaccine offers a solution to end this epidemic.'' Unlike other AIDS vaccines under development, the Skinner HIV-VAC AIDS vaccine is based on a unique approach to neutralizing the AIDS virus that promises to be effective with the AIDS virus' many mutant forms. This method of vaccine preparation is based on a unique intracellular vaccine technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines. This has been under development by Dr. Skinner and his team for the past 10 years at the University of Birmingham, United Kingdom. Pre-clinical testing of the Skinner HIV-VAC AIDS vaccine is nearing completion, with Phase I & II testing underway in Russia at the Russia AIDS Centre. The Russian phase of the vaccine development program will be headed up by Dr. Vadim Pokrovsky at the Russia AIDS Centre, which has particular expertise in immunology, epidemiology and evaluation of efficacy and safety testing of vaccines. The United Nations estimates that there are currently 33 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million. Sales of anti-HIV drugs increased to more than $3 billion last year and could reach $6 billion in coming years. The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here. -------------------------------------------------------------------------------- Contact: HIV-VAC, Inc. Phil Flynn, 800/392-7961